HUTCHMED (NASDAQ:HCM) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• HUTCHMED has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, reflecting a change in analyst sentiment.
• Despite the downgrade, Zacks Research maintains a "strong-buy" rating for the stock, indicating mixed opinions among analysts with an average target price of $28.00.
• HUTCHMED's stock performance shows a one year low of $11.51 and a high of $21.50, with the stock opening at $15.97 recently.

Wall Street Zen downgraded shares of HUTCHMED (NASDAQ:HCM - Free Report) from a buy rating to a hold rating in a research note published on Sunday.

A number of other research analysts have also recently weighed in on HCM. Zacks Research upgraded HUTCHMED to a "strong-buy" rating in a research report on Monday, August 11th. HSBC downgraded HUTCHMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Bank of America lifted their price objective on HUTCHMED from $27.00 to $28.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $28.00.

HUTCHMED Stock Up 9.5%

HCM traded up $1.56 during trading on Friday, reaching $17.93. The company's stock had a trading volume of 92,782 shares, compared to its average volume of 51,431. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $21.50. The company's fifty day moving average price is $16.46 and its 200-day moving average price is $15.41. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.65 and a quick ratio of 4.51.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HCM. Ameriprise Financial Inc. grew its stake in shares of HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company's stock valued at $234,000 after buying an additional 698 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of HUTCHMED by 49.6% during the 4th quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock valued at $39,000 after buying an additional 899 shares during the period. M&G PLC grew its stake in shares of HUTCHMED by 0.4% during the 2nd quarter. M&G PLC now owns 259,617 shares of the company's stock valued at $3,894,000 after buying an additional 924 shares during the period. Summit Trail Advisors LLC grew its stake in shares of HUTCHMED by 7.7% during the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock valued at $212,000 after buying an additional 1,004 shares during the period. Finally, Barclays PLC grew its stake in shares of HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after buying an additional 2,255 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.